"My impression of the Avelumab/Axitinib data is that it is a bit underwhelming, I think Nivo/Ipi looks stronger."
not sure how you get there from here. CM514 failed in PFS for total population compared to sunitinib and patients with good prognosis did better on sunitinib than nivo/ipi. Then we have Pal's recent comments on problems associated with nivo/ipi. This could be really important in elderly patients or those with comorbidities. The increase in treatment related deaths appears to be higher with avel/axi than sunitinib and that may give BMY some hope but Javelin results look to be significantly better than CM514 on almost every other metric.